MarketCap
Facebook
X
TelegramQuarterly report 2026-Q1
added 05-05-2026
IQVIA Holdings Revenue 2011-2026 | IQV
Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.
Traditionally defined as follows:Revenue = Price * Quantity of productsRevenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]
This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.
Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.
Annual Revenue IQVIA Holdings
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 16.3 B | 15.4 B | 15 B | 14.4 B | 13.9 B | 11.4 B | 11.1 B | 10.4 B | 9.74 B | 6.88 B | 5.74 B | 5.46 B | 5.1 B | 4.87 B | 4.33 B |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 16.3 B | 4.33 B | 10 B |
Quarterly Revenue IQVIA Holdings
| 2026-Q1 | 2025-Q4 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 4.15 B | - | 4.02 B | 3.83 B | - | 3.9 B | 3.81 B | 3.74 B | - | 3.74 B | 3.73 B | 3.65 B | - | 3.56 B | 3.54 B | 3.57 B | - | 3.39 B | 3.44 B | 3.41 B | 3.3 B | 2.79 B | 2.52 B | 2.75 B | 2.9 B | 2.77 B | 2.74 B | 2.68 B | 2.69 B | 2.59 B | 2.57 B | 2.56 B | 2.52 B | 2.46 B | 2.38 B | 2.32 B | - | 1.5 B | 1.55 B | 1.49 B | - | 1.42 B | 1.44 B | 1.35 B | - | 1.4 B | 1.34 B | 1.31 B | - | 1.2 B | 1.3 B | 1.23 B | - | 1.2 B | 1.23 B | 1.16 B | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 4.15 B | 1.16 B | 2.57 B |
References
- Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).
Revenue of other stocks in the Diagnostics research industry
| Issuer | Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
128 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Castle Biosciences
CSTL
|
344 M | $ 20.03 | 4.32 % | $ 581 M |  USA |
 |
Fulgent Genetics
FLGT
|
283 M | $ 16.41 | 2.88 % | $ 496 M | USA |
 |
Guardant Health
GH
|
982 M | $ 114.97 | 17.09 % | $ 14.4 B | USA |
 |
ICON Public Limited Company
ICLR
|
5.48 B | $ 115.09 | 1.36 % | $ 9.49 B |  Irlanda |
 |
Interpace Biosciences
IDXG
|
38.7 M | $ 1.8 | - | $ 7.96 M | USA |
 |
Agilent Technologies
A
|
6.32 B | $ 113.78 | 2.96 % | $ 34.6 B | USA |
 |
Illumina
ILMN
|
4.37 B | $ 141.92 | 0.17 % | $ 22.6 B | USA |
 |
Co-Diagnostics
CODX
|
622 K | $ 2.39 | 21.32 % | $ 3.18 M | USA |
|
Akumin
AKU
|
750 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Aspira Women's Health
AWH
|
343 K | - | -6.19 % | $ 10.5 M | USA |
 |
Accelerate Diagnostics
AXDX
|
2.97 M | - | -61.36 % | $ 2.46 M | USA |
 |
Biocept
BIOC
|
25.9 M | - | -13.05 % | $ 7.29 M | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
73.7 M | - | - | $ 562 M |  Britain |
 |
CareDx, Inc
CDNA
|
380 M | $ 21.15 | 3.02 % | $ 1.13 B | USA |
 |
Chembio Diagnostics
CEMI
|
49.5 M | - | 0.22 % | $ 16.8 M | USA |
 |
HTG Molecular Diagnostics
HTGM
|
6.37 M | - | -20.0 % | $ 1.06 M | USA |
 |
Lantheus Holdings
LNTH
|
1.54 B | $ 96.09 | 3.44 % | $ 6.49 B | USA |
 |
Medpace Holdings
MEDP
|
2.53 B | $ 421.87 | 0.47 % | $ 12.2 B | USA |
 |
Mettler-Toledo International
MTD
|
4.03 B | $ 1 082.67 | 3.04 % | $ 22.3 B |  Schweiz |
 |
Global Cord Blood Corporation
CO
|
1.24 B | - | - | $ 399 M |  China |
 |
National Research Corporation
NRC
|
137 M | $ 19.26 | 2.72 % | $ 431 M | USA |
 |
Fluidigm Corporation
FLDM
|
138 M | - | 1.08 % | $ 308 M | USA |
 |
Genetic Technologies Limited
GENE
|
6.79 M | - | - | $ 7.1 B |  Australia |
 |
Natera
NTRA
|
820 M | $ 204.92 | 4.53 % | $ 20.2 B | USA |
 |
Genetron Holdings Limited
GTH
|
651 M | - | 0.12 % | $ 80.1 M | China |
 |
DermTech
DMTK
|
15.3 M | - | -11.32 % | $ 2.94 M | USA |
 |
Personalis
PSNL
|
69.6 M | $ 7.95 | 12.93 % | $ 709 M | USA |
 |
Charles River Laboratories International
CRL
|
4.02 B | $ 156.03 | 2.36 % | $ 7.73 B | USA |
 |
PRA Health Sciences, Inc.
PRAH
|
3.18 B | - | - | $ 10.7 B | USA |
 |
Enzo Biochem
ENZ
|
31.9 M | - | -8.98 % | $ 14.8 K | USA |
 |
NeoGenomics
NEO
|
727 M | $ 8.9 | 6.08 % | $ 1.14 B | USA |
 |
Exact Sciences Corporation
EXAS
|
3.25 B | - | - | $ 19.8 B | USA |
 |
Myriad Genetics
MYGN
|
824 M | $ 3.81 | 7.32 % | $ 353 M | USA |
 |
Heska Corporation
HSKA
|
257 M | - | - | $ 1.31 B | USA |
 |
Koninklijke Philips N.V.
PHG
|
17.8 B | $ 26.74 | 2.65 % | $ 25.4 B |  Niderland |
 |
Thermo Fisher Scientific
TMO
|
44.6 B | $ 451.79 | 0.89 % | $ 170 B | USA |
 |
Senseonics Holdings
SENS
|
35.3 M | $ 5.71 | 3.07 % | $ 238 M | USA |
 |
Twist Bioscience Corporation
TWST
|
377 M | $ 53.66 | 8.4 % | $ 3.21 B | USA |
 |
QIAGEN N.V.
QGEN
|
2.25 B | - | - | $ 10.6 B | Niderland |
 |
Soleno Therapeutics
SLNO
|
190 M | - | - | $ 2.69 B | USA |
 |
Biomerica
BMRA
|
5.31 M | $ 2.35 | -1.26 % | $ 5.4 M | USA |
 |
Trinity Biotech plc
TRIB
|
61.6 M | $ 0.6 | 6.95 % | $ 216 M | Irlanda |
 |
Laboratory Corporation of America Holdings
LH
|
14 B | $ 257.42 | 1.47 % | $ 21.4 B | USA |
 |
Waters Corporation
WAT
|
932 M | $ 341.32 | 2.42 % | $ 20.3 B | USA |
 |
Motus GI Holdings
MOTS
|
319 K | - | -34.28 % | $ 263 K |  Israel |
 |
Neogen Corporation
NEOG
|
895 M | $ 8.83 | 5.75 % | $ 1.92 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
11 B | $ 193.75 | 1.92 % | $ 21.5 B | USA |